These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 28405498)

  • 1. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
    Klein C; Waldhauer I; Nicolini VG; Freimoser-Grundschober A; Nayak T; Vugts DJ; Dunn C; Bolijn M; Benz J; Stihle M; Lang S; Roemmele M; Hofer T; van Puijenbroek E; Wittig D; Moser S; Ast O; Brünker P; Gorr IH; Neumann S; de Vera Mudry MC; Hinton H; Crameri F; Saro J; Evers S; Gerdes C; Bacac M; van Dongen G; Moessner E; Umaña P
    Oncoimmunology; 2017; 6(3):e1277306. PubMed ID: 28405498
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    van Brummelen EMJ; Huisman MC; de Wit-van der Veen LJ; Nayak TK; Stokkel MPM; Mulder ER; Hoekstra OS; Vugts DJ; Van Dongen GAMS; Verheul HM; Evers S; Tessier JJL; Saro J; Schellens JHM; Menke-van der Houven van Oordt CW
    Oncotarget; 2018 May; 9(37):24737-24749. PubMed ID: 29872502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.
    Waldhauer I; Gonzalez-Nicolini V; Freimoser-Grundschober A; Nayak TK; Fahrni L; Hosse RJ; Gerrits D; Geven EJW; Sam J; Lang S; Bommer E; Steinhart V; Husar E; Colombetti S; Van Puijenbroek E; Neubauer M; Cline JM; Garg PK; Dugan G; Cavallo F; Acuna G; Charo J; Teichgräber V; Evers S; Boerman OC; Bacac M; Moessner E; Umaña P; Klein C
    MAbs; 2021; 13(1):1913791. PubMed ID: 33974508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
    Peters S; Angevin E; Alonso-Gordoa T; Rohrberg K; Melero I; Mellado B; Perez-Gracia JL; Tabernero J; Adessi C; Boetsch C; Watson C; Dal Porto J; Dejardin D; Del Nagro C; Nicolini V; Evers S; Klein C; Leutgeb B; Pisa P; Rossmann E; Saro J; Umana P; Charo J; Teichgräber V; Steeghs N
    Clin Cancer Res; 2024 Apr; 30(8):1630-1641. PubMed ID: 38319672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.
    Ribba B; Boetsch C; Nayak T; Grimm HP; Charo J; Evers S; Klein C; Tessier J; Charoin JE; Phipps A; Pisa P; Teichgräber V
    Clin Cancer Res; 2018 Jul; 24(14):3325-3333. PubMed ID: 29463551
    [No Abstract]   [Full Text] [Related]  

  • 6. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8
    Tichet M; Wullschleger S; Chryplewicz A; Fournier N; Marcone R; Kauzlaric A; Homicsko K; Deak LC; Umaña P; Klein C; Hanahan D
    Immunity; 2023 Jan; 56(1):162-179.e6. PubMed ID: 36630914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8
    Codarri Deak L; Nicolini V; Hashimoto M; Karagianni M; Schwalie PC; Lauener L; Varypataki EM; Richard M; Bommer E; Sam J; Joller S; Perro M; Cremasco F; Kunz L; Yanguez E; Hüsser T; Schlenker R; Mariani M; Tosevski V; Herter S; Bacac M; Waldhauer I; Colombetti S; Gueripel X; Wullschleger S; Tichet M; Hanahan D; Kissick HT; Leclair S; Freimoser-Grundschober A; Seeber S; Teichgräber V; Ahmed R; Klein C; Umaña P
    Nature; 2022 Oct; 610(7930):161-172. PubMed ID: 36171284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Tumor Responses with Sequential Targeted α-Particles Followed by Interleukin 2 Immunocytokine Therapies in Treatment of CEA-Positive Breast and Colon Tumors in CEA Transgenic Mice.
    Minnix M; Kujawski M; Poku E; Yazaki PJ; Wong JY; Shively JE
    J Nucl Med; 2022 Dec; 63(12):1859-1864. PubMed ID: 35772959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
    Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
    Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
    Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
    Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
    Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
    Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
    Gadwa J; Amann M; Bickett TE; Knitz MW; Darragh LB; Piper M; Van Court B; Bukkapatnam S; Pham TT; Wang XJ; Saviola AJ; Deak LC; Umaña P; Klein C; D'Alessandro A; Karam SD
    Cell Rep Med; 2023 Aug; 4(8):101150. PubMed ID: 37586327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b Study of the Immunocytokine Simlukafusp alfa (FAP-IL2v), in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma.
    Hansen AR; Gomez-Roca CA; Robbrecht DGJ; Verlingue L; Italiano A; Bauman JE; Steeghs N; Prenen H; Fayette J; Spicer J; Niu J; Habigt C; Schneider M; Evers S; Sleiman N; Dejardin D; Ardeshir C; Schmid D; Boetsch C; Charo J; Kraxner A; Teichgräber V; Keshelava N; Bonomi MR
    Clin Cancer Res; 2024 Oct; ():. PubMed ID: 39422604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8
    LaPorte KM; Hernandez R; Santos Savio A; Malek TR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37270181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy.
    Murer P; Brannetti B; Rondeau JM; Petersen L; Egli N; Popp S; Regnier C; Richter K; Katopodis A; Huber C
    MAbs; 2024; 16(1):2381891. PubMed ID: 39041287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition.
    Codarri Deak L; Hashimoto M; Umaña P; Klein C
    Oncoimmunology; 2023; 12(1):2197360. PubMed ID: 37025392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation.
    Kujawski M; Sherman M; Hui S; Zuro D; Lee WH; Yazaki P; Sherman A; Szpikowska B; Chea J; Lasiewski D; Poku K; Li H; Colcher D; Wong J; Shively JE
    Oncoimmunology; 2020; 9(1):1724052. PubMed ID: 32117587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
    Steeghs N; Gomez-Roca C; Rohrberg KS; Mau-Sørensen M; Robbrecht D; Tabernero J; Ahmed S; Rodríguez-Ruiz ME; Ardeshir C; Schmid D; Sleiman N; Watson C; Piper-Lepoutre H; Dejardin D; Evers S; Boetsch C; Charo J; Teichgräber V; Melero I
    Clin Cancer Res; 2024 Jul; 30(13):2693-2701. PubMed ID: 38630781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Viitanen R; Virtanen H; Liljenbäck H; Moisio O; Li XG; Nicolini V; Richard M; Klein C; Nayak T; Jalkanen S; Roivainen A
    Front Immunol; 2022; 13():901693. PubMed ID: 35874707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.
    Gellert J; Jäkel A; Danielczyk A; Goletz C; Lischke T; Flechner A; Dix L; Günzl A; Kehler P
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.